GLP-1 Insurance Coverage Expands in 2026: State-by-State Update

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Eli Lilly’s orforglipron (Foundayo) was FDA approved for weight loss in 2026, offering a new oral GLP-1 option.
Medicare has launched a temporary program covering GLP-1s for obesity, as detailed by CMS and KFF.
The FDA clarified rules for compounded GLP-1s on April 1, 2026, stating semaglutide and tirzepatide are not on the 503B bulks list or drug shortage list.
A preliminary FDA evaluation, updated January 13, 2026, found no causal link between GLP-1 RAs and suicidal thoughts or actions.

The landscape of GLP-1 medication access and regulation is undergoing significant changes in 2026, bringing both new opportunities and clearer guidelines for patients and providers. A major development is the FDA's approval of Eli Lilly’s orforglipron, known as Foundayo, which represents the first small-molecule GLP-1 receptor agonist available in pill form for weight loss, offering a potentially more convenient option for many individuals. Simultaneously, Medicare has initiated a temporary program to cover GLP-1 medications specifically for obesity, a move that could significantly broaden access for beneficiaries. On the regulatory front, the FDA issued updated policies for compounders on April 1, 2026, clarifying the conditions under which compounded GLP-1 drugs are permissible, including specific guidance on substances like semaglutide and tirzepatide. Furthermore, the agency provided an update on January 13, 2026, regarding its ongoing evaluation of reports concerning suicidal thoughts or actions with GLP-1 RAs, stating that preliminary findings do not suggest a causal link. These changes collectively shape a new era for GLP-1 treatment, impacting everything from drug availability and insurance coverage to safety perceptions and compounding practices.

What's New in GLP-1 Approvals for 2026?

The year 2026 marks a significant milestone in the treatment of obesity with the approval of a novel oral GLP-1 medication. Eli Lilly’s orforglipron, marketed under the brand name Foundayo, secured FDA approval for weight loss. This approval is especially noteworthy because Foundayo is the first small-molecule GLP-1 receptor agonist to receive such clearance, setting it apart from the established peptidic GLP-1-based obesity drugs that typically require injections. The availability of an oral GLP-1 option could dramatically change how these medications are perceived and used by patients and healthcare providers.

The Rise of Oral GLP-1s

For years, GLP-1 receptor agonists have been recognized for their effectiveness in managing type 2 diabetes and promoting weight loss. However, many of these medications have been administered via injection, which can be a barrier for some patients due to discomfort, needle phobia, or the inconvenience of regular injections. The introduction of an oral GLP-1 receptor agonist like Foundayo addresses these concerns directly. This pill format offers a convenience edge that could improve patient adherence and overall access to GLP-1 therapy. The FDA's decision to approve Foundayo highlights a growing trend towards more patient-friendly drug delivery methods in the obesity treatment landscape.

The approval of Foundayo in 2026 is a game-changer, not just for Eli Lilly, but for the entire field of weight management. It opens up possibilities for a broader range of patients to benefit from GLP-1 treatment. Patients who may have been hesitant to start injectable medications now have a powerful oral alternative. This innovation could lead to higher rates of treatment initiation and persistence, ultimately improving public health outcomes related to obesity. The convenience factor of a pill cannot be overstated, as it removes a significant hurdle that many individuals face when considering long-term medication use.

Impact on the GLP-1 Market

The entry of Foundayo into the market will likely spark increased competition and innovation among pharmaceutical companies developing GLP-1 medications. As the first small-molecule GLP-1 receptor agonist, it paves the way for future research into similar oral compounds. This could lead to a more diverse array of treatment options, potentially driving down costs and making these life-changing medications more accessible to a wider population. The approval of Foundayo is not just about a single drug; it represents a shift in the treatment paradigm for obesity, emphasizing convenience and patient preference alongside efficacy.

The implications for insurance coverage are also substantial. As a newly approved, convenient oral option, Foundayo might see different coverage patterns compared to its injectable counterparts. Insurance providers often evaluate drugs based on their efficacy, safety, and cost-effectiveness. The convenience of an oral pill could be a strong argument for broader coverage, especially if it leads to better adherence and long-term health benefits. This approval, announced by Nature.com, underscores the ongoing evolution in GLP-1 therapies and their potential to transform obesity care. The information about this approval was detailed in an article titled FDA approves GLP-1 pill for obesity, published in 2026. This move by the FDA signifies a commitment to expanding effective and accessible treatment options for individuals struggling with obesity.

The development pipeline for GLP-1s is active, as indicated by the Prime Therapeutics GLP-1 Pipeline Update from February 2026, which outlines ongoing research and development in this class of drugs. This continuous innovation ensures that new and improved options will keep emerging, further enhancing the choices available to patients. The approval of Foundayo is a testament to the scientific advancements in understanding and targeting GLP-1 receptors, offering hope to millions seeking effective weight management solutions. This new oral medication adds another powerful tool to the arsenal against obesity, complementing the existing injectable options and providing a more flexible approach to treatment.

How Does Medicare Coverage for GLP-1s Change in 2026?

Medicare has introduced a significant new initiative in 2026 with a temporary program designed to cover GLP-1 medications for obesity. This "Medicare GLP-1 Bridge" program, as detailed by the Centers for Medicare & Medicaid Services (CMS), represents a substantial shift in how Medicare beneficiaries can access these crucial weight-loss drugs. For many years, Medicare Part D plans typically did not cover medications solely for weight loss. This temporary program aims to bridge that gap, providing much-needed access for eligible individuals.

Understanding the Medicare GLP-1 Bridge

The Centers for Medicare & Medicaid Services (CMS) has published specific information regarding this initiative on its official website, under the heading Medicare GLP-1 Bridge | CMS. This program is a direct response to the growing recognition of obesity as a chronic disease requiring medical intervention, and the proven efficacy of GLP-1 receptor agonists in managing it. The program is designed to provide temporary coverage, indicating that while it offers immediate relief for beneficiaries, its long-term status may be subject to further evaluation and policy changes.

This temporary coverage is a significant development for the millions of Americans who rely on Medicare for their healthcare needs. Previously, many beneficiaries faced high out-of-pocket costs or complete lack of coverage for GLP-1s if they were prescribed primarily for weight loss. The new program aims to alleviate this financial burden, making these effective medications more attainable. The KFF, an independent source for health policy research, has also highlighted the importance of this program in their quick take, titled What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. They emphasize the profound impact this will have on beneficiaries who previously had limited options for medically supervised weight management.

Eligibility and Access

While the specifics of eligibility and how beneficiaries can enroll in the "Medicare GLP-1 Bridge" program are outlined by CMS, the general intent is to provide access to those who meet specific medical criteria for obesity and for whom GLP-1 medications are deemed appropriate by their healthcare providers. This temporary program acknowledges the health benefits associated with weight loss, including the reduction of risks for other chronic conditions such as type 2 diabetes, heart disease, and certain cancers. By covering these medications, Medicare is taking a proactive step towards improving the overall health and well-being of its enrollees.

The introduction of this program also underscores the evolving understanding of obesity within the medical community and among policymakers. No longer is obesity simply viewed as a lifestyle choice but rather a complex disease influenced by various physiological, genetic, and environmental factors. Providing coverage for effective pharmacological treatments like GLP-1s is a critical component of a comprehensive approach to managing this public health challenge. The temporary nature of the program suggests that CMS may be evaluating its effectiveness, cost-implications, and the broader impact on beneficiary health before considering a more permanent policy change.

Future Outlook for Medicare Coverage

The "Medicare GLP-1 Bridge" in 2026 could serve as a precursor to more permanent and comprehensive Medicare coverage for obesity medications. Its implementation signals a recognition of the clinical value of GLP-1s for weight loss and the need to address the unmet medical needs of Medicare beneficiaries. As the program progresses, data collected on patient outcomes, medication adherence, and overall healthcare costs will likely inform future policy decisions. This temporary bridge is a crucial step forward, offering a glimmer of hope for millions of older adults and individuals with disabilities who have been waiting for Medicare to cover these transformative treatments for obesity. The financial implications of GLP-1 medications are significant, as discussed in "GLP-1 Medication Costs in 2026: Insurance Coverage, Savings Programs, and What Patients Actually Pay," published in April 2026, making Medicare's temporary coverage even more vital for affordability.

The program also highlights the ongoing dialogue between government agencies, healthcare providers, and patient advocacy groups regarding access to innovative treatments. As the medical evidence supporting GLP-1s for obesity continues to grow, so does the pressure on insurance providers, including government programs like Medicare, to adapt their coverage policies. This temporary measure is a testament to that pressure and the collective effort to ensure that effective treatments are not out of reach for those who need them most.

What Are the FDA's Latest Rules for Compounded GLP-1s?

The FDA issued a significant update on April 1, 2026, clarifying its policies for compounders regarding GLP-1 medications. These updated guidelines aim to ensure the safety and efficacy of compounded drugs, especially as the national supply of commercially available GLP-1s begins to stabilize. The FDA reminds compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B of the FD&C Act. This means that not all compounded versions of GLP-1s are legally or safely produced.

Understanding Section 503A Guidelines

Under section 503A, a compounded drug product is generally intended for an individual patient based on a prescription. A key restriction is that compounders should not regularly or in "inordinate amounts" compound drugs that are "essentially copies" of commercially available products. The FDA considers a compounded drug product to be "essentially a copy" if it has the same active pharmaceutical ingredient(s) (API) as a commercially available drug in the same, similar, or easily substitutable strength, and can be used by the same route of administration. This rule applies unless a prescriber determines and documents that the compounded product contains a change that produces a significant difference for an identified individual patient.

For example, the FDA may consider a compounded product combining semaglutide API and another API, like vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available semaglutide product. This would be the case when the drug products are used by the same route of administration, such as an injectable, and the amounts of semaglutide and vitamin B12 in the compounded product are within 10% of the strengths of the respective commercially available products. This "within 10%" rule provides a clear benchmark for what constitutes an "essentially copy" drug. However, the FDA has stated that it does not intend to take action against a compounder for regularly compounding an "essentially copy" drug product if they fill four or fewer prescriptions of that compounded drug product during a calendar month. This allows for limited, individualized compounding without triggering enforcement actions.

Restrictions Under Section 503B

Outsourcing facilities, operating under section 503B, face even stricter regulations. These facilities are generally restricted from compounding drugs using bulk drug substances (API) unless two specific conditions are met: either the bulk drug substance appears on the "503B bulks list" identifying substances for which there is a clinical need, or the drug compounded from the bulk drug substance is on FDA’s drug shortage list at the time of compounding, distribution, and dispensing.

Crucially, as of the April 1, 2026, update, tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. This means that outsourcing facilities are generally prohibited from compounding these GLP-1 medications from bulk drug substances. This clarifies a critical aspect of compounded GLP-1 availability, directly impacting the types of facilities that can legally produce these drugs. The FDA's guidance, outlined in FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, serves to protect patients by ensuring that compounded drugs meet appropriate safety and quality standards.

Implications for Patients and Prescribers

These updated FDA rules have significant implications for both patients seeking GLP-1 medications and prescribers considering compounded options. Patients should be aware that not all compounded GLP-1 products are created equal or are legally produced. It is essential to verify that any compounded medication comes from a facility adhering to FDA guidelines and that there is a documented medical reason for a compounded version over a commercially available one. Prescribers must carefully consider the FDA's guidance when prescribing compounded GLP-1s, particularly regarding the "essentially a copy" rule and the restrictions on outsourcing facilities for tirzepatide and semaglutide. The agency intends to consider a compounded drug product to be essentially a copy of a commercially available drug product if it contains the same active pharmaceutical ingredient(s) (API) as the commercially available drug product in the same, similar or an easily substitutable strength. This rigorous stance aims to ensure patient safety and maintain the integrity of the pharmaceutical supply chain.

The FDA's proactive stance on compounded drugs is particularly important given the high demand for GLP-1 medications. While compounding can play a vital role in providing access to medications for patients with specific needs, it must be done within a strict regulatory framework to prevent the distribution of unsafe or ineffective products. This April 1, 2026, update provides much-needed clarity for the industry and ensures that patient health remains the top priority. The "FDA has stated, at this time, it does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month." This specific allowance provides a narrow pathway for limited compounding under controlled circumstances.

Is There a Link Between GLP-1s and Suicidal Thoughts?

The FDA has been actively evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This evaluation is part of the agency's ongoing commitment to drug safety. As of an update on January 13, 2026, a preliminary review of the available data has not found evidence to suggest that the use of these medicines causes suicidal thoughts or actions.

FDA's Ongoing Safety Evaluation

The FDA initiated its evaluation due to reports linking GLP-1 RAs to suicidal ideation and behavior. This class of medicines is widely used to treat individuals with type 2 diabetes and to assist those with obesity or who are overweight in achieving weight loss. Given the broad use of these medications, any potential safety concern is taken seriously by the agency. The initial findings, however, provide reassurance to patients and healthcare providers.

On January 13, 2026, the FDA issued a Drug Safety Communication, providing an update on this ongoing evaluation. This communication clarified that based on their preliminary assessment, a causal link between GLP-1 RAs and suicidal thoughts or actions has not been established. This is a crucial piece of information for patients who may have concerns about the mental health side effects of these medications. The FDA's statement helps to address anxieties and provides a more informed perspective on the safety profile of GLP-1 RAs. The agency's preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions.

What the Data Shows So Far

The preliminary evaluation involved a thorough review of various data sources, including adverse event reports submitted to the FDA. While reports of suicidal thoughts or actions were evaluated, the agency's analysis did not reveal a direct causal relationship. It is important to remember that many factors can contribute to mental health conditions, and correlation does not always equal causation. Patients taking GLP-1 RAs may also have underlying health conditions or other risk factors for suicidal thoughts or actions.

The FDA's transparent approach to this safety evaluation is commendable. By providing regular updates, such as the one on January 13, 2026, the agency ensures that the public and medical community are kept informed with the most current data. This allows healthcare providers to counsel their patients effectively and for individuals to make informed decisions about their treatment options. The FDA's ongoing monitoring of drug safety is a continuous process, and they remain vigilant in assessing any new information that emerges.

Reassurance for Patients

For individuals currently taking GLP-1 RAs for type 2 diabetes or weight management, the FDA's preliminary findings offer significant reassurance. It suggests that the benefits of these medications, which include improved glycemic control and substantial weight loss, can continue to be pursued without undue concern about a direct link to suicidal thoughts or actions. However, as with any medication, patients should always discuss any new or worsening symptoms, including changes in mood or behavior, with their healthcare provider.

The FDA's commitment to patient safety is paramount, and their comprehensive review process is designed to identify and address potential risks. "Our preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions," stated the FDA in their January 13, 2026, update. This statement, from Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity, is critical for clarifying the safety profile of these widely used drugs. The agency will continue its evaluation and will communicate any new findings as they become available, ensuring that the safety information for GLP-1 RAs remains current and accurate. This robust safety communication process helps maintain public trust in regulated medications and supports informed clinical practice.

What Does the GLP-1 Pipeline Look Like for 2026?

The GLP-1 medication landscape is dynamic, with continuous advancements and new drug candidates emerging from research and development. In February 2026, Prime Therapeutics released a comprehensive GLP-1 Pipeline Update, offering insights into the future of these transformative medications. This update provides a snapshot of the various GLP-1 receptor agonists and related compounds that are currently under investigation, in clinical trials, or awaiting regulatory approval. The pipeline reflects the intense interest and investment in developing more effective, convenient, and targeted treatments for type 2 diabetes and obesity.

Innovations in GLP-1 Research

The GLP-1 pipeline for 2026 is robust, featuring a range of innovative approaches to GLP-1 agonism. This includes not only new formulations of existing GLP-1s but also novel compounds that may offer enhanced efficacy, improved safety profiles, or alternative mechanisms of action. Researchers are exploring various aspects, such as longer-acting formulations that could reduce dosing frequency, combination therapies that target multiple metabolic pathways, and oral forms to improve patient convenience, as exemplified by the recent FDA approval of Eli Lilly’s orforglipron (Foundayo) earlier in 2026.

The focus of the pipeline extends beyond just weight loss and diabetes management. There is growing interest in the potential broader therapeutic applications of GLP-1 receptor agonists, including cardiovascular benefits, kidney protection, and even neuroprotection. These expanded areas of research indicate a deeper understanding of the pleiotropic effects of GLP-1 and its potential to address a wider array of chronic health conditions. The Prime Therapeutics report from February 2026 highlights these diverse avenues of investigation, showcasing the future potential of this drug class.

Key Players and Emerging Compounds

Major pharmaceutical companies, along with smaller biotech firms, are actively involved in advancing GLP-1 research. The Prime Therapeutics GLP-1 Pipeline Update from February 2026 details various compounds in different stages of development, from preclinical studies to late-stage clinical trials. This competitive environment fosters rapid innovation, as companies strive to bring novel and differentiated GLP-1 therapies to market. The ultimate goal is to provide patients with more personalized and effective treatment options that can significantly improve their quality of life and long-term health outcomes.

The continuous influx of new data from clinical trials is crucial for shaping the future of GLP-1 therapy. Each new compound or formulation brings the potential for incremental improvements in efficacy, tolerability, and patient experience. These developments are closely watched by healthcare providers, payers, and patients alike, as they directly impact treatment guidelines, insurance coverage, and overall access to these vital medications. The pipeline update serves as a valuable resource for understanding these evolving trends and anticipating future market changes. The information from this update can be found at GLP-1 Pipeline Update: February 2026 - Prime Therapeutics - Portal.

Anticipating Future Approvals

Based on the current pipeline, it is reasonable to anticipate several new GLP-1 related approvals in the coming years. These could include novel molecules, enhanced formulations of existing drugs, or new indications for currently approved GLP-1s. Each new approval expands the treatment landscape, offering more choices for clinicians to tailor therapies to individual patient needs. The robust pipeline underscores the enduring importance of GLP-1 receptor agonism as a therapeutic strategy and signals a future where even more effective and accessible options will be available to combat the growing challenges of type 2 diabetes and obesity. The continuous evolution of the GLP-1 pipeline ensures that the medical community remains at the forefront of metabolic disease management.

The constant innovation also means that insurance coverage policies will need to adapt. As new drugs are approved, payers will evaluate their clinical value and cost-effectiveness. This dynamic interaction between drug development and coverage decisions will continue to shape patient access to these crucial medications. The February 2026 pipeline update provides a glimpse into this future, indicating a sustained period of growth and development in the GLP-1 space.

How Will Patients Afford GLP-1 Medications in 2026?

Affording GLP-1 medications continues to be a primary concern for many patients, even with expanding insurance coverage. In April 2026, new information became available regarding GLP-1 medication costs, insurance coverage, and various savings programs designed to help patients manage these expenses. Understanding these factors is crucial for anyone considering or currently taking GLP-1 receptor agonists for weight loss or diabetes management. The high list prices of these drugs often necessitate robust insurance coverage or alternative financial assistance.

Navigating Insurance Coverage

Insurance coverage for GLP-1 medications can vary significantly depending on the type of insurance plan, the specific GLP-1 drug prescribed, and the patient's diagnosis. While Medicare has introduced a temporary program for obesity-related GLP-1s in 2026, private insurance plans may have different criteria. Patients need to thoroughly understand their individual insurance benefits, including formularies, deductibles, co-pays, and any prior authorization requirements. Many plans may still require documentation of medical necessity, failed attempts at other treatments, or specific body mass index (BMI) thresholds for coverage, especially when prescribed for weight loss. For diabetes patients weighing which GLP-1 to push their plan toward, our Tirzepatide vs Semaglutide for Diabetes Control: 2026 Head-to-Head compares glycemic outcomes side by side.

The approval of new oral medications like Eli Lilly’s Foundayo in 2026 could also impact coverage dynamics. While oral medications often appear to be more convenient, their initial cost may still be substantial. Insurance companies will evaluate the cost-effectiveness of these new options compared to existing injectables. The availability of more choices could lead to increased competition, which might eventually influence pricing and coverage. Patients should engage directly with their insurance providers to confirm their specific coverage details for prescribed GLP-1 medications.

Leveraging Savings Programs and Discounts

Beyond insurance, numerous savings programs and discounts are available to help patients afford GLP-1 medications. Pharmaceutical manufacturers often offer patient assistance programs, co-pay cards, or discount coupons that can significantly reduce out-of-pocket costs. These programs are designed to make medications more accessible, particularly for those who are uninsured, underinsured, or facing high co-pays. The information published in April 2026 regarding GLP-1 medication costs emphasizes the importance of exploring these avenues.

In addition to manufacturer programs, some pharmacies offer their own discount programs or loyalty schemes. Patients can also look into non-profit organizations that provide financial assistance for medication costs. Exploring all available options can help mitigate the financial burden associated with GLP-1 therapy. When considering compounded versions, patients must also weigh the potential cost savings against the FDA's clarified regulations and the lack of regulatory oversight compared to commercially approved drugs. The April 2026 publication on GLP-1 medication costs highlights these various strategies, providing a comprehensive guide for patients seeking to manage expenses.

Long-Term Financial Planning

Given that GLP-1 medications are often prescribed for long-term use, patients must consider the ongoing financial commitment. Understanding the full cost of therapy, including monthly payments, annual deductibles, and potential changes in insurance coverage, is essential for long-term planning. Healthcare providers can often provide guidance on navigating these financial aspects or refer patients to resources that offer assistance. The continuous evolution of the GLP-1 market, including new approvals and changes in insurance policies, means that patients should regularly review their options and seek updated information on affordability.

The growing recognition of obesity as a chronic disease and the increasing availability of effective treatments are driving changes in how these medications are covered and financed. While challenges remain, the combination of expanding Medicare coverage, new oral drug approvals, and various savings programs offers a more optimistic outlook for patients seeking to afford GLP-1 medications in 2026. Informed decision-making and proactive research into available resources are key to ensuring sustainable access to these transformative therapies. The information on "GLP-1 Medication Costs in 2026: Insurance Coverage, Savings Programs, and What Patients Actually Pay" was medically reviewed and published in April 2026, providing timely guidance on this critical topic.

Frequently Asked Questions

What is orforglipron (Foundayo)?

Orforglipron, known as Foundayo, is a new GLP-1 medication approved by the FDA for weight loss in 2026. It stands out because it is the first small-molecule GLP-1 receptor agonist available in pill form. This oral administration offers a convenience advantage over many existing injectable GLP-1 drugs, potentially making treatment more accessible and easier for patients to adhere to.

Does Medicare cover GLP-1s for weight loss in 2026?

Yes, in 2026, Medicare has launched a temporary program called the "Medicare GLP-1 Bridge" to cover GLP-1 medications for obesity. This is a significant change, as Medicare Part D plans traditionally did not cover drugs solely for weight loss. The program aims to provide access for eligible beneficiaries, as detailed by the Centers for Medicare & Medicaid Services (CMS).

Can I get compounded semaglutide or tirzepatide?

The FDA clarified its policies for compounders on April 1, 2026. While compounding is allowed under specific conditions, semaglutide and tirzepatide do not currently appear on the FDA's 503B bulks list or its drug shortage list. This means outsourcing facilities are restricted from compounding these drugs from bulk substances. Compounded drugs are also considered "essentially a copy" if they match commercially available products in strength and route of administration, with a "within 10%" rule for API amounts.

Are GLP-1 medications safe regarding mental health side effects?

The FDA has been evaluating reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. A preliminary evaluation, updated on January 13, 2026, has not found evidence to suggest that the use of these medicines causes suicidal thoughts or actions. The FDA continues to monitor the safety of these medications and provides updates to the public.

Where can I find more information on GLP-1 insurance coverage?

You can find more information on GLP-1 insurance coverage by consulting your specific insurance provider, checking the Centers for Medicare & Medicaid Services (CMS) website for Medicare details, and reviewing health policy research from organizations like KFF. Additionally, resources like the "GLP-1 Medication Costs in 2026: Insurance Coverage, Savings Programs, and What Patients Actually Pay" article, published in April 2026, provide insights into affordability and savings programs.

Sources

— The The GLP-1 Daily Team